Vericel Q1 Earnings Call Highlights

Vericel NASDAQ: VCEL reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as expected NexoBrid procurement revenue from a new federal contract.

MarketBeat • May 9, 2026

Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript

Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026

Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance

Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91%

GlobeNewsWire • May 7, 2026

Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates

Vericel Corporation (VCEL) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago.

Zacks Investment Research • May 7, 2026

Wall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 53.4% in Vericel (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • May 4, 2026

Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026

CAMBRIDGE, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2026 financial results on Thursday, May 7, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.

GlobeNewsWire • Apr 23, 2026

Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid

CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for the procurement of NexoBrid®, establishment and maintenance of a Vendor Managed Inventory (VMI) system, design and validation of a U.S based manufacturing facility, and the development of a next generation formulation and additional indication for NexoBrid.

GlobeNewsWire • Apr 2, 2026

Vericel Corporation (VCEL) Q4 2025 Earnings Call Transcript

Vericel Corporation (VCEL) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 26, 2026

Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results

Total Revenue of $276.3 Million, with MACI Revenue Growth of 21% to $239.5 Million Net Income Growth of 59% to $16.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% Record Fourth Quarter Gross Margin of 79% and Adjusted EBITDA Margin of 40% Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2025.

GlobeNewsWire • Feb 26, 2026

Vericel Corporation (VCEL) Matches Q4 Earnings Estimates

Vericel Corporation (VCEL) came out with quarterly earnings of $0.45 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.38 per share a year ago.

Zacks Investment Research • Feb 26, 2026